Saveurs et Vie has completed a fundraising
Saveurs et Vie has completed a fundraising with Isatis Capital to develop a new product line and fund acquisitions.
Saveurs et Vie is a leading home care services company specialized in preparing and delivering meals for senior people. The company buys ready-meals from various suppliers and assembles complete meals according to the medical needs of the clients, mostly senior people. Saveurs et Vie acquires news customers directly (B2C) or through contracts with local authorities (B2B2C). The company is the largest in France in this field and has recently developed services for hospitals to help them cope with under-nourished patients.
Oaklins’ team in France advised Saveurs et Vie on its fundraising. The team contacted nearly 25 potential investors, 10 of them showed interest and were ready to send a non-binding offer.
Talk to the deal team
Related deals
Lindenhofgruppe has sold its majority stake in LabPoint to Affidea Switzerland
LabPoint Medical Laboratories AG has been acquired by Affidea Switzerland AG. Through the transaction, Lindenhofgruppe AG gains a strong strategic partner to support the further development of LabPoint and will remain a shareholder with a reduced stake, continuing as a key customer of the company. It lays the foundation for LabPoint’s sustainable development under a new anchor shareholder, with the aim of further strengthening and selectively expanding its position in laboratory diagnostics.
Learn moreEuroHospital Varna has been acquired by Intermedica Group
EuroHospital Varna has been acquired by Intermedica Group, allowing the business to continue to grow and deliver high-quality healthcare services to its patients. Through the transaction, Intermedica Group expands its healthcare presence and intends to build a new model of integrated personalized care focused on preventive, holistic and digital medicine.
Learn moreOlyos Group has acquired a controlling stake in NewScience
Olyos Group has acquired a controlling stake in NewScience from its founders through a transaction structured in two stages, with the strategic objective of ultimately acquiring 100% of the company. The transaction forms part of NewScience’s international growth strategy and a gradual cash-out process for the founder, who intends to complete a full exit. Olyos intends to retain the management team through a put and call option mechanism and an earn-out linked to NewScience’s 2025 EBITDA.
Learn more